New York, Jan 14, 2026, 19:09 EST — After-hours
- Pfizer shares ended the day up 1.7%, closing at $25.58, and showed little movement in after-hours trading.
- CEO Albert Bourla highlighted Pfizer’s eye on a rapidly expanding cash-pay obesity-drug sector, with plans to launch 10 Phase 3 studies for Metsera compounds.
- Attention now turns to Pfizer’s results update scheduled for Feb. 3 and the upcoming ex-dividend date on Jan. 23.
Shares of Pfizer (PFE.N) climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector.
The stock closed regular hours roughly 1.7% higher, settling at $25.58. After-hours trading remained subdued.
The obesity story is crucial for Pfizer as it seeks to regain steady growth following the drop-off in COVID-era sales and faces looming patent expirations on major drugs that could invite cheaper competitors.
Management has warned investors that the coming years may bring some volatility. Obesity stands out as one of the few sizable markets that could shift Pfizer’s trajectory—if the company can pull it off.
At the J.P. Morgan Healthcare Conference, Pfizer CEO Albert Bourla admitted the company underestimated how fast out-of-pocket demand would grow for weight-loss drugs, even when insurance doesn’t cover them. “Now we see that this operates almost like Viagra, where people were willing to pay and buy it, although it was not reimbursed at all,” he said. Pfizer aims to start 10 Phase 3 trials for its Metsera obesity drugs by year-end. “We are all in on obesity,” Bourla emphasized. Reuters
Eli Lilly and Novo Nordisk are steering the market today as the scramble for next-gen weight-loss drugs heats up. Viking Therapeutics CEO Brian Lian noted that strategic interest is “probably broader than is visible … more parties sort of circling around the space and very intrigued.” Reuters
Pfizer isn’t the only player looking to expand beyond current GLP-1 drugs, which imitate gut hormones to reduce appetite and slow digestion. AbbVie has been promoting an amylin-based strategy — amylin being a pancreas hormone that also dampens appetite — positioning it as a possible alternative route for obesity treatment.
Wednesday’s rally stood out amid a weaker broader market, as investors sifted through big-bank earnings and fresh economic reports. This environment pushed stock-pickers to focus sharply on individual company stories.
Pfizer investors are focused on timing: how fast the company can push its Metsera pipeline into late-stage trials and, down the line, product launches—all while controlling costs and maintaining strong execution.
The downside scenario is well-known. Pfizer’s profit forecast for 2026 already trails Wall Street expectations, with management warning of setbacks from patent expirations and declining COVID product revenue — risks that could overshadow future pipeline gains if trial outcomes falter or pricing changes.
Pfizer’s next major event is set for Feb. 3, when it will release its fourth-quarter and full-year results and hold an analyst call at 10 a.m. EST.
Dividend-focused investors have their eyes on Pfizer’s upcoming ex-dividend date, set for Jan. 23. The firm’s next quarterly payment of $0.43 is scheduled for March 6, per Pfizer’s investor site.
Heading into Thursday, traders are focused on whether drugmakers linked to obesity will see continued momentum. Attention also turns to any new insights from recent conference meetings, while Pfizer’s Feb. 3 update hangs over market positioning.
